 "Administering the right dose")
Panacea Biotec has surged 10% to Rs 127 on the BSE in intra-day trade in an otherwise weak market after the company announced the launch of tetravalent vaccine Easyfour-TT for active primary immunisation and booster dose against diphtheria, tetanus and pertussis (DTP) and haemophilus influenza type B (Hib).
“Easyfour-TT is a sterile and uniform suspension, manufactured using CDAP technology with WHO pre-qualified antigens which ensures good quality, high immunogenicity and less reactogenicity,” Panacea Biotec said in a press release.
Being fully liquid, product requires with a legacy of being a tried and tested brand in pediatric clinical trials ensuring good ethnic response with a better reactogenicity profile, it added.
At 12:03 pm; the stock was up 5% at Rs 120 on the BSE as compared to 1% decline in the S&P BSE Sensex. A combined 290,235 shares changed hands on the counter on the BSE and NSE so far.
“Easyfour-TT is a sterile and uniform suspension, manufactured using CDAP technology with WHO pre-qualified antigens which ensures good quality, high immunogenicity and less reactogenicity,” Panacea Biotec said in a press release.
Being fully liquid, product requires with a legacy of being a tried and tested brand in pediatric clinical trials ensuring good ethnic response with a better reactogenicity profile, it added.
At 12:03 pm; the stock was up 5% at Rs 120 on the BSE as compared to 1% decline in the S&P BSE Sensex. A combined 290,235 shares changed hands on the counter on the BSE and NSE so far.
